Cancer cells are killed when something damages them beyond repair or triggers their self-destruct program. This happens through several distinct mechanisms: treatments that shatter their DNA, immune cells that punch holes in their membranes, drugs that remove their disguises so the immune system can find them, and engineered cells designed to hunt them down. Understanding how each approach works helps clarify why cancer treatment often involves combining strategies and why some cancers respond better to certain therapies than others.
How Cells Normally Self-Destruct
Every cell in your body carries a built-in demolition system called apoptosis. When a cell detects that its DNA is too damaged to fix, or it receives specific chemical signals from neighboring cells, it activates a chain reaction that dismantles it from the inside. This is the mechanism that most cancer treatments try to trigger.
The process works through two routes. The intrinsic pathway fires when something inside the cell goes wrong: oxygen deprivation, loss of growth signals, or severe stress. A protein punches holes in the cell’s energy-producing structures (mitochondria), releasing a molecule that assembles a destruction complex. This complex activates a cascade of enzymes that chop up the cell’s internal machinery in an orderly way, breaking it into small pieces that nearby cells absorb without causing inflammation.
The extrinsic pathway starts from the outside. Immune cells or signaling molecules latch onto specific “death receptors” on the cancer cell’s surface. This binding assembles a different destruction complex on the inner side of the cell membrane, which activates the same chain of demolition enzymes. Both pathways converge on the same endpoint: the cell dies cleanly and gets recycled. Cancer cells often survive precisely because they’ve found ways to disable one or both of these pathways, which is why treatments need to overwhelm those defenses.
DNA Damage: How Chemotherapy Works
Most chemotherapy drugs kill cancer cells by inflicting so much DNA damage that the cell can’t divide anymore. Some drugs create chemical bonds between the two strands of the DNA double helix, essentially gluing them together. These “crosslinks” are extraordinarily difficult for cells to repair because both strands are involved simultaneously. When the cell tries to copy its DNA to divide, it hits these crosslinks and stalls. If it can’t fix the problem, it triggers apoptosis.
Other chemotherapy drugs work by mimicking the building blocks of DNA. When the cell incorporates these fake building blocks during replication, the new DNA strand is defective. Still others interfere with the molecular machinery that separates chromosomes during cell division, causing the process to fail catastrophically.
The reason chemotherapy causes side effects like hair loss, nausea, and immune suppression is straightforward: these drugs target rapidly dividing cells, and cancer cells aren’t the only ones dividing quickly. The cells lining your gut are among the fastest-dividing in the body, which is why nausea and digestive problems are so common. Bone marrow cells, which produce blood and immune cells, are also highly vulnerable. Hair follicle cells divide rapidly too. The collateral damage to these tissues is essentially the price of using a weapon that can’t fully distinguish friend from foe.
Radiation: Breaking DNA With Energy
Radiation therapy kills cancer cells by using high-energy beams to snap their DNA strands. The most lethal form of damage is a double-strand break, where both rails of the DNA ladder are severed at nearly the same spot. These breaks are considered the most destructive type of DNA damage in biology because they can cause the cell to lose entire chunks of genetic information.
Radiation doesn’t just cut DNA directly. Much of its killing power comes from an indirect route: the beams split water molecules inside cells into highly reactive fragments called free radicals. These free radicals then ricochet around the cell’s interior, slashing into DNA and other critical structures. Since cells are roughly 70% water, this indirect damage multiplies the effect of every beam that enters the tumor.
Modern radiation therapy uses precise imaging to aim beams at tumors from multiple angles, concentrating the dose where it’s needed while minimizing exposure to surrounding tissue. But some damage to nearby healthy cells is unavoidable, which is why radiation is typically delivered in small daily doses over several weeks. This gives normal cells time to repair between sessions, while cancer cells, which often have defective repair systems, accumulate fatal damage.
Your Immune System’s Built-In Cancer Killers
Your body has specialized immune cells that patrol for and destroy abnormal cells every day. Natural killer cells are among the most important. When a natural killer cell identifies a cancer cell, it presses up against it and releases two key proteins from small storage packets called granules.
The first protein, perforin, punches tiny pores into the cancer cell’s outer membrane. These pores are about 16 nanometers across. The second group of proteins, called granzymes, are enzymes that slip through those pores into the cancer cell’s interior. Once inside, granzymes trigger the apoptosis cascade, essentially hijacking the cell’s self-destruct system. The cancer cell initially tries to patch the holes in its membrane, but the granzymes have already entered and begun the demolition process. The cell dies from the inside out.
This system works constantly, catching and eliminating cells that are starting to behave abnormally. Cancer develops when cells manage to evade this surveillance, either by suppressing the signals that would mark them as targets or by actively shutting down the immune cells that find them.
Checkpoint Inhibitors: Removing Cancer’s Disguise
One of the most significant advances in cancer treatment exploits the way cancer cells hide from the immune system. Many tumors produce large amounts of a protein on their surface that acts like a fake ID badge. When a T cell (an immune cell that kills threats) bumps into a cell displaying this protein, it receives an “off” signal and backs away. The cancer cell essentially tells the T cell, “I’m normal, leave me alone.”
Checkpoint inhibitor drugs block this interaction. They physically prevent the cancer cell’s deceptive surface protein from connecting with the T cell’s receptor. With the “off” signal blocked, T cells recognize the cancer cell as a threat and attack it.
The results have been dramatic for certain cancers. In metastatic melanoma, a cancer that was nearly always fatal just 15 years ago, combination checkpoint inhibitor therapy now produces median survival times of over six years. Long-term data from a landmark trial showed that roughly half of patients treated with a combination of two checkpoint inhibitors survived cancer-free for 10 or more years. These numbers represent one of the most striking improvements in cancer survival in modern oncology.
Checkpoint inhibitors don’t work equally well for all cancers. They tend to be most effective against tumors with many genetic mutations, because those mutations create more abnormal proteins for the immune system to recognize once the disguise is removed.
CAR-T Cell Therapy: Custom-Built Cancer Hunters
CAR-T cell therapy takes a patient’s own immune cells and engineers them into precision-guided weapons. Doctors collect T cells from the patient’s blood and send them to a laboratory, where scientists genetically modify them to produce a new receptor on their surface called a chimeric antigen receptor, or CAR.
Each CAR is designed to recognize a specific protein found on the surface of the patient’s cancer cells. The receptor spans the T cell’s membrane: the outer portion contains fragments of lab-made antibodies that lock onto the target protein, while the inner portion contains signaling components that activate the T cell when the receptor finds its target. Once infused back into the patient, these modified T cells circulate through the body, latch onto any cell displaying the target protein, and kill it. They also multiply after finding their targets, creating an expanding army of cancer-hunting cells.
CAR-T therapy has produced remarkable results in certain blood cancers, particularly in patients who had exhausted all other options. It is less effective so far against solid tumors, partly because the dense, hostile environment inside solid tumors makes it harder for T cells to penetrate and survive.
Starving Cancer’s Altered Metabolism
Cancer cells fuel themselves differently than normal cells. Most healthy cells generate energy efficiently using oxygen. Cancer cells, even when oxygen is plentiful, rely heavily on a faster but less efficient process that burns through enormous amounts of glucose. This quirk, known as the Warburg effect, has been recognized for nearly a century but has only recently become a serious treatment target.
Cancer cells compensate for their inefficient energy production by dramatically increasing the number of glucose transporters on their surface, essentially opening more doors to pull sugar in faster. They also ramp up several key enzymes in their sugar-processing pathway. Each of these proteins represents a potential target. Drugs designed to block these transporters or enzymes could theoretically starve cancer cells while leaving normal cells, which don’t depend on the same metabolic shortcuts, relatively unharmed.
This metabolic difference is already exploited in diagnosis: PET scans detect cancer by tracking where the body is consuming the most glucose, since tumors light up due to their extreme sugar appetite. Turning that same vulnerability into an effective treatment is an active area of drug development, with several compounds showing promise in early testing.
Why Combination Therapy Is Standard
Cancer cells are genetically unstable, which means they mutate rapidly. In any tumor, there are likely subpopulations of cells with slightly different vulnerabilities. A treatment that kills 99% of the tumor may leave behind a small group of cells that happen to be resistant, and those survivors can regrow the tumor. This is why oncologists rarely rely on a single approach.
Combining treatments that kill cancer through different mechanisms, such as pairing chemotherapy with immunotherapy or using radiation alongside checkpoint inhibitors, attacks the tumor on multiple fronts simultaneously. A cell that survives DNA damage from chemotherapy may still be vulnerable to an immune attack unmasked by a checkpoint inhibitor. This layered strategy reduces the odds that any resistant subpopulation can survive and repopulate the tumor.